Exchange: NYSE·Updated 05:49 PM EDT

TFX News

News
all
press releases
Should You Continue to Hold TMO Stock in Your Portfolio?
Thermo Fisher's growth is gaining momentum as acquisitions strengthen its life sciences reach, but macro risks and competition remain concerns.
Zacks
More News
Teleflex Features Innovative Dynetic-35 Balloon-Expandable Cobalt Chromium Stent System at CIRSE 2026
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today announced it will showcase innovative technologies at CIRSE 2026 in Copenhagen, reinforcing its commitment to advancing innovation for healthcare providers. Among the featured technologies will be the...
Business Wire
Medtronic Q1 Earnings & Revenues Top Estimates, Stock Up in Pre-Market
MDT beats Q1 earnings and revenue estimates as broad-based growth drives shares higher and prompts a fiscal 2027 guidance boost.
Zacks
Is This the Right Time to Add CRL Stock to Your Portfolio?
Charles River's improving DSA demand and strategic investments support growth, but uneven recovery and NHP cost volatility remain key risks.
Zacks
Should You Add Illumina Stock to Your Portfolio Now?
ILMN's sequencing growth, oncology momentum and multiomics expansion support its outlook, though cost volatility may pressure margins.
Zacks
Should You Add Teleflex Stock to Your Portfolio Now?
TFX's Vascular growth, Interventional expansion and improved leverage support its outlook, while currency volatility remains a key risk.
Zacks
Is This the Right Time to Hold Medtronic Stock in Your Portfolio?
MDT's Cardiovascular gains and renal denervation growth offer upside, but tariffs and currency headwinds cloud its outlook.
Zacks
TFX or PEN: Which Is the Better Value Stock Right Now?
TFX vs. PEN: Which Stock Is the Better Value Option?
Zacks
Is it Worth Adding Veracyte Stock to Your Portfolio Now?
VCYT's Afirma and Decipher sales momentum supports growth, while competition, macro pressures and rising investments remain key concerns.
Zacks
Is TFX a Buy Now as Valuation Improves but Execution Risks Remain?
Valuation is improving for Teleflex, but slower Vascular Intervention integration and margin pressure keep execution risks in focus.
Zacks

Advertisement|Remove ads.